Skip to content
Search AI Powered

Latest Stories

Personalized Vaccines May Be the Future of Battling Cancer

A recent study details a key breakthrough in cancer treatment.

Make us preferred on Google

Cancer is a demon that doctors have desperately tried to exorcise for decades. It is the body turned against itself, where the natural programming of healthy cells runs amok. The dysregulation of the orderly signaling pathways is linked to the balance between cellular growth and cellular specialization of the cell life cycle. The result is unrestrained cellular proliferation accumulating into large tumors that interrupt the normal functions of vital organs.

Since cancerous cells are derived from normal cells of the body, the human immune system does not see them as disease because the immune system is trained only to distinguish between “self” and “non-self.” This prevents the body from attacking itself, though disorders where this mechanism fails are known as autoimmune diseases.


A recent study published by Tanyi et al. (2018) in Science Translational Medicine appears to have made a breakthrough in this area, where a successful ovarian cancer vaccine was produced and clinically evaluated that was personalized to each patient.

The human immune system can be basically divided into two parts: a non-specific initial response and a highly specific follow up response. When a foreign disease-causing agent or pathogen invades the body, the first line of defense is immediate and not targeted exclusively to the particular pathogen. This is merely a stop-gap measure to keep the pathogen at bay until the secondary adaptive response can be formulated by the body to eliminate the invader either through antibody producing B-cells or killer T-cells.

Once the disease agent has been thwarted, the adaptive immune system “remembers” the solution in the form of memory cells. This way, if the body encounters the same pathogen again, it will recall the tool used to combat it and can promptly deploy a solution. This is the basis behind vaccines: to introduce the immune system to a pathogen in a safe and controlled manner, so it can develop a suitable response and will remember how to react should it come across that pathogen again.

Edward Jenner was able to deduce that there was a subpopulation of people that survived smallpox infections who had previously been exposed to a related virus: cowpox. Cowpox was capable of infecting and replicating in humans, though the symptoms were much milder and the human immune system could easily adapt and clear the virus, unlike its human counterpart. And those persons exposed to cowpox did not succumb to the brutal effects of smallpox; somehow these people were protected. Thus, Jenner posited that if people were inoculated with cowpox that they would be protected against smallpox.

This strategy represented the first recorded instance of a vaccination program. Cowpox was found to be sufficiently similar to smallpox, that the memory cells of the immune system could be tricked into seeing smallpox as cowpox. The scientists of the current study have endeavored to trick the immune system into recognizing certain cancers as foreign, thus triggering the immune response.

The notion of vaccinating against different forms of cancer is complicated by the fact that the disease is propagated by a person’s own cells, which are treated as “self” by the immune system. Therefore, research scientists have sought to trick the adaptive immune system to seeing cancer cells as “non-self” and thus attack them. The key has been to identify features of cancer cells that are distinct from normal cells so that tumors are targeted while non-malignant cells are safe from a cross-reactive autoimmune reaction.

This is where the current study on personalized ovarian cancer vaccination comes in: where the scientists looked for ways to stimulate an immune response to what are known as “neo-antigens.”

Traditional cancer vaccines are often rendered ineffective over time due to progressive accumulation of mutations in cancer cells as they evolve, which produce new antigens (or neo-antigens) on the cancer cell surface. Thanks to advances in modern gene sequencing and computational algorithms, these neo-antigens are being detected with greater frequency and accuracy.

A major partnership between the Cancer Research Institute in New York and the Parker Institute for Cancer Immunotherapy in San Francisco spearheads such efforts as the Tumor Neo-antigen Selection Alliance. This can allow for specific cancer immunotherapies to be devised that will hopefully replace and be more efficacious than traditional non-specific regimens such as chemotherapy and radiation. In contrast to self-antigens associated with tumors, killer T-cell responses cells can be generated from neo-antigens. Also, the immune responses elicited by neo-antigens do not appear to induce autoimmune reactions to normal healthy cells that could produce toxic side effects.

With respect to developing a vaccine against ovarian cancer, other factors have thwarted these efforts that were also addressed in the current study. Specialized immune cells known as T-regulatory cells reside within ovarian tumors, which suppress the activity of killer T-cells. Furthermore, these tumors also prevent the activation and entry of killer T-cells in the tumor through the secretion of a substance known as vascular endothelial growth factor A (or VEGF-A). Two treatments already exist to counteract these factors: an antibody that blocks VEGF-A called bevacizumab and cyclophosphamide that attenuates T-regulatory cell activity.

In the final years of the Obama administration, Vice President Joseph Biden was tasked with coordinating a national medical effort to implement what was termed “precision medicine.” This represents a customized approach to an individual’s healthcare with treatments and other products being tailored on a person-to-person basis. This approach was used in the Tanyi study for how it initiated an immune response to neo-antigens relevant to ovarian cancer.

Cancer cells were harvested from an individual’s ovarian tumor cells, which was subject to a mild acid treatment exposing hidden cancer antigens. These were then mixed with specialized immune-related cells also collected from the patient called dendritic cells that present foreign antigens to effectors of the adaptive immune response: antibody producing B-cells and killer T-cells. These dendritic cells were injected back into the patient intranodally.

The Tanyi study also incorporated bevacizumab and cyclophosphamide into some of the regimens alone or in combination. The patients that received the intranodal dendritic cell injection in combination with both bevacizumab and cyclophosphamide resulted in the best survival outcome with no recurrence of ovarian cancer one to two years post-immunization. Notably, the subjects receiving all three treatments produced the most robust and significantly active immune response to a variety of neo-antigens.

These findings suggest a new era is on the horizon for cancer patients. Indeed, it is highly likely that there will be more research efforts like this one in the near future, as the “precision medicine” initiative pushed by former Vice President Biden was fruitful in the passage of the “21st Century Cures Bill” that provided 6.3 billion dollars in new research funding for fighting cancer in this way. One of the last pieces of legislation signed by former President Obama is likely to have a positive impact in the lives of cancer patients well into the future.

More from News/science

Nicholas Hoult; Robert Pattinson
Taylor Hill/FilmMagicl; Lia Toby/Getty Images for BFI

Fans Think Nicholas Hoult Already Knew He Wasn't Cast As James Bond In Awkward Interview Days Before Robert Pattinson Was Announced

In case you missed it, Daniel Craig's reign as Agent 007 has officially come to a close.

After years of speculation that everyone from Idris Elba to Jacob Elordi would be the next James Bond, it was announced Monday that Robert Pattinson will be taking over the role in the as yet unnamed next iteration of the franchise.

Keep ReadingShow less
Screenshot of James P. Sullivan
@atrupar/X

Trump Judicial Nominee Epically Flails During Confirmation Hearing After Being Asked Simple Question About Constitution

James P. Sullivan, President Donald Trump's nominee to serve on the U.S. Court for the Western District of Texas, was criticized after he completely flubbed a simple question about the 22nd Amendment of the U.S. Constitution.

Senator Chris Coons of Delaware, a Democrat, began his line of questioning by asking Sullivan if he can "just tell me what the 22nd Amendment provides."

Keep ReadingShow less
Mariah Carey; Nick Cannon
Ilya S. Savenok/Getty Images for Gucci; Johnny Nunez/WireImage

Mariah Carey's Kids With Nick Cannon Call Out His 'Unsustainable' Lifestyle In New Docuseries Trailer—And Fans Are Seated

Nick Cannon makes the news most often now for his support of MAGA Republican President Donald Trump, his sexist double standards for his teenage daughter, and the number of children he's had with multiple women, with seven of the 12 arriving between December of 2020 and December of 2022.

Elon Musk still has him beat with numbers—14 children—but is behind Cannon with women, with only four mother's of his children to Cannon's six.

Keep ReadingShow less
Lauren Boebert; Donald Trump; Barack Obama
Joe Raedle/Getty Images; Aaron Favila/POOL/AFP via Getty Images; Alex Wong/Getty Images

Lauren Boebert Resurfaces Trump's Mind-Numbing 2014 Dig About Obama Amid Tech Outages—And Nobody's Laughing

Outgoing Colorado Republican Representative Lauren Boebert was harshly criticized after she revived President Donald Trump's racist conspiracy theory "joke" from 2014 about former President Barack Obama amid tech outages.

Trump has long embraced the reactionary politics that gave rise to the Tea Party movement, a conservative populist social and political movement that called for lower taxes and for a reduction of the national debt and federal budget deficit.

Keep ReadingShow less
Screenshot of Donald Trump
@Acyn/X

Trump 'Jokes' About Wanting Same Honor Bestowed On General MacArthur During Philippines Visit—And We're Cringing Hard

President Donald Trump had observers cringing after he, speaking in the Philippines, quipped that he wanted to have the same honor bestowed upon him that General Douglas MacArthur once did, referring to a title conferred to him by former Philippine President Manuel Quezon.

Trump landed in the Philippines on Tuesday. He is expected to meet with regional partners and formalize a trade deal. His trip abroad, the first since Republicans lost seats to Democrats in the midterm blue wave, will include three-way nuclear talks with Chinese President Xi Jinping and Russian President Vladimir Putin.

Keep ReadingShow less